Public Assessment Report Mutual Recognition …
PAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION
Download Public Assessment Report Mutual Recognition …
Information
Domain:
Source:
Link to this page:
Documents from same domain
The Human Medicines Regulations 2012 – …
www.mhra.gov.ukThe Human Medicines Regulations 2012 – description of each Part This document provides a brief overview of each Part of the Human Medicines Regulations 2012 …
FULTIUM -D 800 IU CAPSULES - GOV.UK
www.mhra.gov.ukVitamin D deficiency, with levels of 25(OH)D below 25nmol/L (10ng/ml), could result in the disease rickets (or osteomalacia). The disease resulting as a deficiency is considered to be due to malabsorption
GLYCOPYRRONIUM BROMIDE 0.2MG/ML …
www.mhra.gov.ukUKPAR Glycopyrronium Bromide 0.2 mg/ml Solution for Injection PL 00156/0115 1 GLYCOPYRRONIUM BROMIDE 0.2MG/ML SOLUTION FOR INJECTION (PL 00156/0115)
Meloxicam - GOV.UK
www.mhra.gov.ukPL 31388/0003-4 UKPAR Alpex Pharma (UK) Ltd, Meloxicam 7.5mg and 15mg Orodispersible Tablets 3 Scientific Discussion INTRODUCTION Based on the review of the data on quality, safety and efficacy, the UK granted
PL 00010/0643 - GOV.UK
www.mhra.gov.ukUKPAR Canesten HC Cream PL 00010/0643 6 All excipients comply with their respective European Pharmacopoeia monographs, except triceteareth-4-
Public Assessment Report UKPAR Canesten Combi …
www.mhra.gov.ukThis is a summary of the Public Assessment Report (PAR) for Canesten Combi Pessary & External Cream 500mg / 2% w/w pessary & cream (PL 00010/0653).
DCPAR for Ampicillin-Salbactam 1 g--0 5 and 2 g-1 g ...
www.mhra.gov.ukPAR Ampicillin/Sulbactam 1 g/0.5 g and 2 g/1 g powder for Solution for Injection or Infusion UK/H/4322/001-2/DC 1 Public Assessment Report Decentralised Procedure
Cefixime 400 mg Film-coated Tablets, PL 22805 …
www.mhra.gov.ukMHRA PAR; CEFIXIME 400 MG FILM-COATED TABLETS, PL 22805/0032-3 2 Lay summary The Medicines and Healthcare products Regulatory Agency …
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC
Perindopril/Indapamide 2mg/0.625mg and …
www.mhra.gov.ukUKPAR Perindopril/Indapamide 2mg/0.625 and 4mg/1.25mg Tablets PL 20092/0058-9 2 Perindopril/Indapamide 2mg/0.625mg and 4mg/1.25mg Tablets PL 20092/0058-9
Related documents
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzVersion: pfddepoi11017 Supersedes: pfddepoi11016 . Page 2 of 18 . 4.2 Dose and method of administration . Ovulation suppression . DEPO-PROVERA should be vigorously shaken just before use to ensure that the dose being
PROVERA Medroxyprogesterone acetate - Medsafe
www.medsafe.govt.nzDATA SHEET . PROVERA ® Medroxyprogesterone acetate . 2.5 mg, 5 mg, 10 mg, 100 mg and 200 mg tablets . PRESENTATION PROVERA tablets contain medroxyprogesterone acetate (MPA) as the active ingredient.
Approved Prescription Products for Menopausal …
www.menopause.org4 Continued from page 3 Estradiol acetate* Femring† Moderate to severe vasomotor symptoms due to menopause Moderate to severe vulvar and vaginal atrophy due to
USPI medroxyprogesterone acetate - Depo …
www.pfizer.com2 Medroxyprogesterone acetate, administered parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative endometrium into
New contraceptive eligibility checklists for provision …
www.who.intNew contraceptive eligibility checklists for provision of combined oral contraceptives and depot-medroxyprogesterone acetate in community-based programmes
SAYANA PRESS 104 mg/0.65 ml suspension for …
www.medicines.org.ukPage 1 of 15 Package leaflet: Information for the user SAYANA PRESS® 104 mg/0.65 ml suspension for injection medroxyprogesterone acetate Single-dose container ...